Both should have significant catalysts by the end of the decade.Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is probably not it. Some research suggests that the overwhelming majority of day traders not only fail to beat the market, but actually lose money over the long run.A better strategy is to invest in quality stocks with attractive long-term prospects, a ...

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 12, Leonid Timashev from RBC Capital reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a price target of $77.00. Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying Legend Biotech Corporation (NASDAQ:LEGN) reported CARVYKTI net trade sales of around $439 million in fiscal Q2 2025, with CARVYKTI demonstr ...

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring patients receive the care they need at the earliest opportunity.The global TSIX clinical study involved more than 13,000 participants, validating performance across a diverse population that reflects real-world healthcare settings.1,2 Basel, 30 September 2025 - Roche (SIX: R ...

A股市场整体表现 - 节前最后一个交易日A股红盘震荡，科创50指数半日大涨2%续创近4年新高，市场呈现科技成长领涨、板块轮动加速特征 [1] - 上证指数早盘低开后震荡回升，午间收涨0.4%报3878.13点，深证成指涨0.31%，创业板指微涨0.06% [2] - 全市场超2900只个股上涨，涨停个股集中在存储芯片、有色金属等领域，主力资金向科技成长板块聚集 [2] - 两市成交额显著放量，A股半日成交达1.37万亿元，显示资金在假期前保持积极交投意愿 [1] 科技成长板块表现 - 半导体产业链与新能源赛道形成双主线，存储芯片概念股在涨价消息发酵下再度爆发，板块内多股涨停 [1][2] - 半导体板块全面走强，板块内多股大涨续创历史新高，AI芯片与先进制造需求成为核心驱动力 [2] - 锂电产业链维持强势，板块内多股连板，储能与动力电池需求支撑板块延续热度 [1][2] - 通信板块下跌1.65%，部分AI硬件方向出现获利盘出逃，CPO概念领跌，反映科技板块内部轮动加速 [3] 资源与周期板块表现 - 有色金属板块领涨两市，板块内多股涨停，受益于新能源产业链需求旺盛及全球大宗商品价格反弹 [2] - 现货黄金升破3860美元/盎司，年内累涨超47%，黄金股集体走强，铜业股同步上扬 [3] - 港股能源板块受国际油价拖累显著，能源业指数下跌1.67%拖累大盘表现 [2][3] - 传统周期板块在政策预期转向与外部需求疲软下持续承压 [3] 港股市场表现 - 港股市场三大指数走势分化，恒生指数微跌0.1%报26596.9点，恒生科技指数逆势上扬0.55%报6358.85点 [1][2] - 港股半导体与黄金股表现活跃，生物医药股延续涨势，创新药板块受政策边际改善预期提振 [1][3] - 濠赌股、内银股同步走弱，日常消费零售指数下跌1.20%，节前消费板块未能延续旺季行情 [3] 金融与消费板块表现 - A股传统金融板块集体调整，银行、保险、券商板块跌幅居前，市场对节前政策利好兑现后的获利了结压力有所显现 [3] - 次新股板块走弱，短期市场风险偏好转向业绩确定性强的主线品种 [3] 市场展望与投资主线 - 节前市场或延续科技成长主线，但需警惕获利了结压力，节后随着政策工具落地与季末流动性改善，科技成长与高端制造仍是资金焦点 [1] - 建议关注半导体全产业链，存储芯片涨价与国产替代加速形成业绩弹性 [3] - 新能源上游资源品在储能与动力电池需求拉动下，供需错配逻辑强化，叠加政策性金融工具支持 [3] - 黄金等避险资产在地缘风险与全球流动性宽松预期下，配置价值凸显 [3] - 中长期看，人工智能+与高端制造仍是政策支持重点，半导体、有色金属、国防军工等行业具备政策红利与产业趋势共振逻辑 [4]

此次要约收购中支付的每股普通股 97.00 美元的收购价格较 Merus 2025 年 9 月 26 日的收盘价 68.89 美 元溢价约 41%，较 Merus 30 天成交量加权平均价 67.42 美元溢价约 44%。 来源：市场资讯 （来源：求实药社） 当地时间 9 月 29 日，Genmab A/S 和 Merus NV 今日宣布，双方已达成交易协议。根据协议，Genmab 拟以每股 97.00 美元的价格全现金收购 Merus 的全部股份。此次收购将以现金方式进行，交易价值约为 80 亿美元。 该交易已获得两家公司董事会的一致批准。Genmab 的全资子公司将对 Merus 100% 的普通股发起要约 收购，预计将于 2026 年第一季度初完成。 | 0 = 00 | CARD STORE FOR CONSULTION CONSULTION CONSULTION OF CONSULTION OF | | --- | --- | | [ Global M Genmab | Nealthcare Professionals Patterco & Care Partnerships Contact AND ...

收购交易概述 - 公司以每股97美元现金收购Merus N V 交易总额约80亿美元[1][6] - 交易预计于2026年第一季度初完成 将显著增强公司肿瘤治疗产品组合[1][3] 战略价值与业务影响 - 获得Merus三期临床阶段资产petosemtamab 加速公司向全所有权模式转型[3][6] - 收购后公司将拥有四个专有项目 推动多款新药上市并多元化收入来源[4] - 交易支持公司持续增长至未来十年 强化其在制药行业地位[3][4] 市场反应与股价表现 - Merus股价在公告后上涨38% 显示市场对交易持积极态度[5] - Leerink Partners给予公司34美元目标价 较当前29.33美元存在16.61%上行空间[2][6] - 公司股票当日交易区间28.36-29.34美元 年内波动区间17.24-29.52美元[2][5] 公司基本面 - 当前市值约185.1亿美元 纳斯达克日成交量503万股[4] - 股价近期微涨0.89% 单日变动0.26美元[2]

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate (“DCR”) and 37% (15/41) objective response rate (“ORR”) in evaluable anti-PD-1 naïve patients per RECIST 1.174% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.115.5 months median Overall Survival (“mOS”) in evaluable anti-PD-1 naïve patients11.4 months mOS in evaluable anti-PD-1 resis ...

公司活动与参与者 - 公司举行网络直播 由首席财务官Matthias Bodenstedt主持 [1] - 公司联合创始人兼首席科学官Kristian Reich 联合创始人兼首席执行官Jorge da Silva参与活动 [1] - 公司邀请HS领域领先专家Professor Alexa Kimball参与 并将对VELA数据发表见解 [1] 活动议程与资料 - 活动议程包括数据展示 专家评论以及最后的问答环节 [1] - 演示文稿文件和演示重播将在公司投资者关系网站moonlaketx.com上提供 [2]

Accessibility StatementSkip Navigation JERSEY CITY, N.J., Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW)Â a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has priced a public offering of securities as described below for aggregate gross proceeds to the Company of $ million, before deducting a ...